Cipla Chief Calls For Invigorating Focus On Repurposed Drugs
Cipla chairman underscores the potential and value of repurposing drugs for Indian researchers and pharma firms looking to build their R&D activities, amid signs of growing attention to the promising area globally.
You may also be interested in...
A small Cambridge, UK-based company, which is more at home partnering with the pharma industry than competing with it, is readying its run into the diabetes space with its ultra-rapid acting insulin. Scrip talked to its CEO to about the company’s biggest year yet.
Work is under way on a new European procedure for repurposing off-patent medicines for new uses. It would mainly be used for active substances where there was more than one marketing authorization holder and the relevant data were generated by a third party.
Cipla’s chair Dr Yusuf Hamied highlighted a series of ‘landmarks’ along the company’s journey at its recent annual general meeting and also indicated that the firm’s tenofovir prodrug, currently in early stage development, could potentially challenge TAF.